Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Louise Soo-Yee Tan"'
Autor:
Louise Soo Yee Tan, Benjamin Wong, Nagaraja Rao Gangodu, Andrea Zhe Ern Lee, Anthony Kian Fong Liou, Kwok Seng Loh, Hao Li, Ming Yann Lim, Andres M. Salazar, Chwee Ming Lim
Publikováno v:
OncoImmunology, Vol 7, Iss 11 (2018)
Cetuximab immunotherapy targeting the epidermal growth factor receptor (EGFR) has been used to treat nasopharyngeal cancer (NPC) with some success. Therefore, combining an immune adjuvant to boost the immune microenvironment may improve its clinical
Externí odkaz:
https://doaj.org/article/27f9db9d56734352801c1895d20e80dd
Publikováno v:
Oral Oncology. 84:61-70
Undifferentiated Nasopharyngeal carcinoma (NPC) is ubiquitously identified with the Epstein-Barr virus (EBV), making this cancer a suitable candidate for cellular-based immunotherapy (CBI) due to its expression of potentially targetable tumor-associa
Autor:
De Yun Wang, Petersson Fredrik, Feng Gang Yu, Chwee Ming Lim, Louise Soo Yee Tan, Boon Cher Goh, Liang Ker, Kwok Seng Loh
Publikováno v:
Oncotarget
Human papillomavirus (HPV), especially HPV16 genotype, is associated with oropharyngeal squamous cell carcinoma (OPSCC). We aim to determine the prevalence and characterize the high-risk (HR)-HPV genotypes in head and neck SCC (HNSCC) in a South-East
Autor:
Yitian Png, See-Voon Seow, Han ChongohOH, Chwee Ming Lim, Min-Han Tan, Swarnalatha Lucky Asidharan, Audrey Zhi Yi Yang, Jamie Mong, Louise Soo-Yee Tan
Publikováno v:
Cancer Immunology Research. 9:PO075-PO075
Background/Aim: To determine if tumor-infiltrating T lymphocytes (TIL T) harvested from EBV-positive Nasopharyngeal cancer (NPC) is an effective source of cellular based immunotherapy. Methods: HLA-A02 Peripheral blood (PB; n=6; paired) and NPC tissu
Autor:
Andrea Zhe Ern Lee, Nagaraja Rao Gangodu, Benjamin Wong, Chwee Ming Lim, Hao Li, Anthony Kian Fong Liou, Andres M. Salazar, Ming Yann Lim, Kwok Seng Loh, Louise Soo Yee Tan
Publikováno v:
OncoImmunology, Vol 7, Iss 11 (2018)
Cetuximab immunotherapy targeting the epidermal growth factor receptor (EGFR) has been used to treat nasopharyngeal cancer (NPC) with some success. Therefore, combining an immune adjuvant to boost the immune microenvironment may improve its clinical